SIS3

Item no.	HY-13013-10mM
Manufacturer	MedChem Express
CASRN	521984-48-5
Amount	10 mM/1 mL
Quantity options	10 mM/1 mL 10 mg 25 mg 2 mg 5 mg
Category	Oncology Neuroscience Neural Lineage Markers Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Neurodegeneration Markers
Type	Inhibitors
Specific against	other
Purity	98.71
Formula	C28H28ClN3O3
Citations	Acta Histochem. 2023 Feb;125(2):152010. Am J Physiol Cell Physiol. 2022 May 18. Am J Physiol Renal Physiol. 2023 Mar 16. Am J Reprod Immunol. 2021 Mar;85(3):e13344. Am J Transl Res. 2020 Feb 15;12(2):478-492. Am J Transl Res. 2021 Sep 15;13(9):10908-10921. Antioxidants (Basel). 2022, 11(12), 2469. Aquaculture. 15 September 2022, 738360. Biochem Pharmacol. 2021 Nov 18;114846. Biochem Pharmacol. 2023 Sep 8;115796. Biochim Biophys Acta Mol Basis Dis. 2018 Nov;1864(11):3824-3836. Biochim Biophys Acta Mol Cell Res. 2022 May 13;1869(9):119285. Biomed Pharmacother. 2023 Jan 11;159:114216. Biomed Pharmacother. 2023 Jul 28;165:115225. BMC Med. 2021 Oct 15;19(1):247. Brain Behav Immun. 2021 Mar 15;S0889-1591(21)00115-X. Brain Res. 2021 Nov 15;147711. Cancer Cell Int. 2024 Mar 25;24(1):114. Cancer Cell. 2024 Apr 8;42(4):682-700.e12. Cell Death Differ. 2021 Mar;28(3):1001-1012. Cell Death Discov. 2021 Oct 4;7(1):273. Chin Med. 2022 Feb 21;17(1):25. Clin Epigenetics. 2023 Nov 11;15(1):182. CNS Neurosci Ther. 2022 Jul 30. Curr Med Sci. 2024 Jun 6. Drug Dev Res. 2023 Oct 2. EMBO Mol Med. 2024 Mar 10. Eur Rev Med Pharmaco. 2021; 25 (2): 787-794. Fish Shellfish Immunol. 2020 Feb;97:455-464. Front Biosci (Landmark Ed). 2024 Sep 24;29(9):336. Front Cell Dev Biol. 2020 Sep 18;8:858. Front Pharmacol. 16 December 2021. Front Pharmacol. 2018 Jun 21;9:660. Immunol Lett. 2019 Feb;206:33-40. Int Immunopharmacol. 2024 Sep 18;142(Pt B):113186. Int J Clin Exp Med. 2016;9(8):15892-15899. Int J Mol Med. 2019 Feb;43(2):993-1002. iScience. 2023 May 29, 106994. J Biol Chem. 2023 Dec 28:105605. J Cell Biochem. 2019 Oct;120(10):17872-17886. J Cell Mol Med. 2021 Nov 9. J Cell Mol Med. 2024 Nov;28(22):e70214. J Cell Physiol. 2023 Jun 25. J Cell Physiol. 2020 Jan;235(1):429-441. J Clin Transl Hepatol. May 26, 2022. J Dent Sci. 2023 Feb 16. J Ethnopharmacol. 2023 Feb 13;307:116243. J Invest Dermatol. 2019 Jan;139(1):224-234. J Pers Med. 2022, 12(3), 385. J Tissue Eng Regen Med. 2021 Aug 7. J Tissue Eng Regen Med. 2022 Feb 23. Life Sci. 2023 Mar 11;320:121540. Med Sci Monit. 2018 Nov 18;24:8290-8297. Mol Immunol. 2018 Nov;103:173-181. Mol Med Rep. 2019 Aug;20(2):1605-1612. Neural Regen Res. 2024 Jan;19(1):180-189. NPJ Regen Med. 2020 Oct 30;5(1):19. Nucleic Acids Res. 2023 Feb 2;gkad043. Oncogenesis. 2021 Oct 27;10(10):72. Parasit Vectors. 2020 Apr 3;13(1):164. Phytother Res. 2022 Oct 10. Redox Biol. 2023 Jun, 102709. Research Square Preprint. 2020 Nov. Research Square Preprint. 2021 May. Research Square Preprint. 2023 Jun 19. Research Square Print. September 15th, 2022. Sci Rep. 2017 Sep 8;7(1):11006. Sci Rep. 2022 Feb 23;12(1):3053. Stem Cell Res. 2020 Dec;49:102099. Wright State University. 2023 Feb 23. Antioxidants (Basel). 2022, 11(12), 2469. Cell Biol Int. 2022 Dec 21. Cell Transplant. 2023 Jan-Dec;32:9636897231162526. Cell Transplant. 2023 Jan-Dec;32:9636897231177356. FASEB J. 2022 Dec;36(12):e22625. J ImmunoTher Cancer. 2020 Aug;8(2):e000422. Theranostics. 2021 May 13;11(14):7110-7125. [1]Jinnin M et al. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol. 2006 Feb;69(2):597-607. [2]Zhu X, et al. Sphingosine kinase 2 cooperating with Fyn promotes kidney fibroblast activation and fibrosis via STAT3 and AKT. Biochim Biophys Acta Mol Basis Dis. 2018 Nov;1864(11):3824-3836. [3]Liu J, et al. Topical TWEAK Accelerates Healing of Experimental Burn Wounds in Mice. Front Pharmacol. 2018 Jun 21;9:660. [4]Li FF, et al. Identification and characterization of an R-Smad homologue (Hco-DAF-8) from Haemonchuscontortus. Parasit Vectors. 2020 Apr 3;13(1):164.
Smiles	[H]Cl.O=C(/C=C/C1=C(N(C2=NC=CC=C21)C)C3=CC=CC=C3)N4CC5=C(CC4)C=C(C(OC)=C5)OC
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	521984-48-5
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	TGF-beta/Smad
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	489.99
Product Description	(E)-SIS3 is a potent and selective inhibitor of Smad3 with an IC50 of 3 μM for Smad3 phosphorylation. (E)-SIS3 inhibits the myofibroblast differentiation of fibroblasts by TGF-β1[1].
Manufacturer - Research Area	Inflammation/Immunology
Solubility	DMSO : 100 mg/mL (ultrasonic)\|H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Stem Cell/Wnt; TGF-beta/Smad
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13013-10mM-safety-datasheet.pdf